a developer of oncolytic immunotherapies
Industry Biotechnology
A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IBIO. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IBIO could also see price increases.
Ticker / NAME | Correlation To REPL | 1D Price Change % | ||
---|---|---|---|---|
REPL | 100% | -2.48% | ||
IBIO - REPL | 35% Loosely correlated | -7.33% | ||
GBIO - REPL | 35% Loosely correlated | -8.20% | ||
SWTX - REPL | 34% Loosely correlated | +5.30% | ||
ZYME - REPL | 32% Poorly correlated | -5.52% | ||
FATE - REPL | 31% Poorly correlated | -4.15% | ||
More |
Ticker / NAME | Correlation To REPL | 1D Price Change % |
---|---|---|
REPL | 100% | -2.48% |
cancer theme (82 stocks) | 35% Loosely correlated | -2.35% |
drugs theme (254 stocks) | 34% Loosely correlated | -1.67% |
immunotherapy theme (12 stocks) | 23% Poorly correlated | -6.14% |
biotechnology theme (238 stocks) | 13% Poorly correlated | -1.76% |